Drug repurposing: Misconceptions, challenges, and opportunities for academic researchers
Drug repurposing is promoted as a cost- and time-effective mechanism for providing new medicines. Often,…
CertaraSeptember 23, 2021
How New FDA Guidance Project Optimus May Affect Future of Oncology Clinical Trials, Drug Pipeline
Julie Bullock, VP, global head of clinical pharmacology and translational medicine at Certara, discusses the…
CertaraAugust 16, 2021
Gene Therapy Based Precision Medicine Therapeutics: Clinical Pharmacology & Translational Science Considerations
The era of gene therapy may have started a couple of decades ago, but approvals…
CertaraAugust 13, 2021
Simcyp Simulator Demonstrates Bioequivalence (BE), Eliminating Need for Costly Clinical Study
In this case study, the sponsor’s closing of a manufacturing site required that one of…
CertaraJuly 29, 2021
Maximizing Oligonucleotide Therapeutic Development: Pre-clinical and Translational Considerations
This is the second of three blog posts discussing best practices for developing oligonucleotide therapeutics.…
CertaraJune 25, 2021
Drive Impactful Science from Bench to Market
Learn how Certara drives impactful science.
CertaraJune 14, 2021
Your First Choice in Complex Biologics Drug Development
The pharmaceutical has made massive investments in complex biologics, a drug class that includes oligonucleotide…
CertaraJune 1, 2021
The Wizard of Oligos: There’s no place like having a successful drug development program!
Oligonucleotide therapies— nucleic acid polymers with the potential to treat or manage a wide range…
CertaraApril 30, 2021
Certara (CERT) – Accelerating Medicines with Biosimulation
As seen on CNBC** Certara is the global leader in biosimulation, a powerful and proven…
CertaraApril 27, 2021
